AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Ophthalmology Drug and Device Market - Growth, Trends, and Forecast (2019 - 2024) - ResearchAndMarkets.com

May 9, 2019

DUBLIN--(BUSINESS WIRE)--May 9, 2019--The “Ophthalmology Drug and Device Market - Growth, Trends, and Forecast (2019 - 2024)” report has been added to ResearchAndMarkets.com’s offering.

The ophthalmology drug and device market is expected to witness a CAGR of 5.3% during the forecast period. Certain factors that are driving the growth of the market include demographic shifts, the impact of the prevalence of eye disease, technological advancements in the field of ophthalmology, and a rising geriatric population.

The cataract volume registered a rapid increase in recent years. The aging population is expected to burden all areas of health care, and ophthalmologists provide approximately 90% of their procedure-based services to seniors. In many countries, cataract surgery is the most frequent surgical procedure performed, and it offers significant improvements in the quality of life of the elderly population at low costs. An increase in the demand for ophthalmological devices projects the future cataract surgery needs that are vital for human health resources and hospitals, and for surgical center management and planning. Other factors, such as the availability of new drugs and devices and the prevalence of eye disease, are also expected to drive the market over the forecast period.

Many regulations are imposed by agencies, such as the FDA, to ensure the safety and efficacy of products. Due to the frequent occurrences of violations, tighter regulations were enforced on label contents. The cost of complying with FDA guidelines is expected to drive many small pharmacies out of business or force them to consolidate. For example, these regulations impose a beyond-use date of only five days for bevacizumab and other biologics. However, it takes 14 days just to test the sterility of these drugs, which means that the regulations for compounded ophthalmology drugs besides bevacizumab, such as ophthalmology mitomycin, and triamcinolone acetonide plus moxifloxacin hydrochloride injection, will become much more expensive or even unavailable. Additionally, increasing healthcare costs and an economic slowdown in developed countries are also restraining the market’s growth.

Companies Mentioned

  • Alcon Inc.
  • Bausch & Lomb Inc.
  • Carl Zeiss Meditec AG
  • Essilor International SA
  • Haag-Streit Group
  • Johnson & Johnson
  • Nidek Co. Ltd
  • Topcon Corporation
  • Ziemer Ophthalmic Systems AG

For more information about this report visit https://www.researchandmarkets.com/r/uqq7ku

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190509005974/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Optical Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY OPTICAL PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/09/2019 04:54 PM/DISC: 05/09/2019 04:53 PM

http://www.businesswire.com/news/home/20190509005974/en